MX9709521A - Compuestos heterociclicos. - Google Patents
Compuestos heterociclicos.Info
- Publication number
- MX9709521A MX9709521A MX9709521A MX9709521A MX9709521A MX 9709521 A MX9709521 A MX 9709521A MX 9709521 A MX9709521 A MX 9709521A MX 9709521 A MX9709521 A MX 9709521A MX 9709521 A MX9709521 A MX 9709521A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- heteroaryl
- endothelin antagonists
- endothelin
- useful
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title abstract 2
- 108050009340 Endothelin Proteins 0.000 title abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invencion se relaciona con compuestos farmacéuticamente utiles de la formula (I), en la cual A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z y R1 tienen cualquiera de los significados definidos en la presente y sus sales farmacéuticamente aceptables, y composiciones farmacéuticas que los contienen. Los compuestos novedosos poseen actividad antagonista del receptor de endotelina y son utiles, por ejemplo en el tratamiento de enfermedades o condiciones médicas en las cuales los niveles elevados o anormales de endotelina juegan un papel causativo significante. La invencion además relaciona procesos para la fabricacion de compuestos novedosos y el uso de los compuestos en el tratamiento médico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9511507.7A GB9511507D0 (en) | 1995-06-07 | 1995-06-07 | Heterocyclic compounds |
| GBGB9519666.3A GB9519666D0 (en) | 1995-09-27 | 1995-09-27 | Heterocyclic derivatives |
| PCT/GB1996/001295 WO1996040681A1 (en) | 1995-06-07 | 1996-06-03 | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9709521A true MX9709521A (es) | 1998-03-31 |
Family
ID=26307176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9709521A MX9709521A (es) | 1995-06-07 | 1996-06-03 | Compuestos heterociclicos. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US5866568A (es) |
| EP (1) | EP0832082B1 (es) |
| JP (1) | JP3193058B2 (es) |
| KR (1) | KR100451523B1 (es) |
| CN (1) | CN1097051C (es) |
| AR (1) | AR003132A1 (es) |
| AT (1) | ATE209200T1 (es) |
| AU (1) | AU715041B2 (es) |
| BR (1) | BR9608611A (es) |
| CA (1) | CA2219742C (es) |
| CZ (1) | CZ289387B6 (es) |
| DE (1) | DE69617236T2 (es) |
| DK (1) | DK0832082T3 (es) |
| EG (1) | EG25227A (es) |
| ES (1) | ES2168487T3 (es) |
| GE (1) | GEP20053470B (es) |
| HR (1) | HRP960272B1 (es) |
| HU (1) | HUP9802300A3 (es) |
| IL (1) | IL122464A (es) |
| MX (1) | MX9709521A (es) |
| MY (1) | MY114926A (es) |
| NO (1) | NO314503B1 (es) |
| NZ (1) | NZ308619A (es) |
| PL (1) | PL187897B1 (es) |
| PT (1) | PT832082E (es) |
| RU (1) | RU2172738C2 (es) |
| SK (1) | SK282338B6 (es) |
| TR (1) | TR199701502T1 (es) |
| TW (1) | TW340845B (es) |
| UA (1) | UA58494C2 (es) |
| WO (1) | WO1996040681A1 (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| WO1997029747A1 (en) | 1996-02-20 | 1997-08-21 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| GB9614804D0 (en) * | 1996-07-15 | 1996-09-04 | Chiroscience Ltd | Resolution process |
| AU6187898A (en) * | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GB9704762D0 (en) | 1997-03-07 | 1997-04-23 | Zeneca Ltd | Chemical process |
| NZ336898A (en) | 1997-04-28 | 2001-10-26 | Texas Biotechnology Corp | Sulfonamides for treatment of endothelin-mediated disorders |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| HUP0201320A2 (en) | 1999-03-19 | 2002-08-28 | Bristol Myers Squibb Co | Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof |
| US6448239B1 (en) * | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
| CN1414965A (zh) | 1999-12-31 | 2003-04-30 | 德州生物科技公司 | 调整内皮肽活性的磺酰胺及其衍生物 |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US7041280B2 (en) | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| RU2234331C1 (ru) * | 2002-12-30 | 2004-08-20 | Смирнов Алексей Владимирович | Лекарственное средство |
| US7169805B2 (en) * | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
| GB0320806D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| GB0403744D0 (en) * | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| KR100839512B1 (ko) * | 2004-07-02 | 2008-06-19 | 주식회사 코오롱 | 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유 |
| EP1791811B1 (en) * | 2004-09-21 | 2009-12-23 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| CN101356179A (zh) | 2004-11-12 | 2009-01-28 | 塔夫茨大学信托人 | 脂肪酶抑制剂 |
| US20070054325A1 (en) * | 2005-04-14 | 2007-03-08 | Reglia | Materials and methods for screening modulators of neural regeneration |
| GB0514743D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Salt |
| ES2385054T3 (es) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
| MX2008011227A (es) * | 2006-03-03 | 2009-02-10 | Torrent Pharmaceuticals Ltd | Receptores antagonistas de accion nueva y doble en los receptores at1 y eta. |
| AU2007237874A1 (en) * | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| AU2007298539B2 (en) * | 2006-09-21 | 2013-05-02 | Piramal Enterprises Limited | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| CL2008000191A1 (es) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
| AP2009005053A0 (en) | 2007-05-03 | 2009-12-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| NZ585310A (en) * | 2007-10-12 | 2012-02-24 | Astrazeneca Ab | Composition 064 |
| ES2676289T3 (es) | 2008-06-19 | 2018-07-18 | Takeda Pharmaceutical Company Limited | Compuesto heterocíclico y su uso |
| HRP20140265T1 (hr) * | 2009-02-06 | 2014-04-25 | Nippon Shinyaku Co., Ltd. | Derivat aminopirazina i odgovarajuä†i lijek |
| CN102491973A (zh) * | 2011-12-15 | 2012-06-13 | 南京友杰医药科技有限公司 | Zd-4054的合成方法 |
| JP2022520206A (ja) * | 2019-02-12 | 2022-03-29 | ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー | 微小血管狭心症 |
| WO2021262998A1 (en) * | 2020-06-25 | 2021-12-30 | Wake Forest University Health Sciences | Compounds for sensing reactive oxygen species and methods for using the same |
| MX2023000276A (es) | 2020-07-10 | 2023-02-09 | Astrazeneca Ab | Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica. |
| AU2022297082B2 (en) * | 2021-06-22 | 2024-04-18 | Alchemedicine, Inc. | Compound, endothelin A receptor antagonist and pharmaceutical composition |
| JP2025526746A (ja) | 2022-08-12 | 2025-08-15 | アストラゼネカ・アクチエボラーグ | 門脈圧亢進症を伴う肝硬変の治療のための併用療法 |
| WO2024166009A1 (en) | 2023-02-08 | 2024-08-15 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of high proteinuria chronic kidney disease |
| WO2025133907A1 (en) | 2023-12-18 | 2025-06-26 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of microvascular angina |
| WO2025163559A1 (en) | 2024-02-01 | 2025-08-07 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for use for the treatment of hypertension |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0655708B2 (ja) * | 1985-05-13 | 1994-07-27 | 三井東圧化学株式会社 | スルホンアミド系化合物及び農業用殺菌剤 |
| RU2043718C1 (ru) * | 1986-01-31 | 1995-09-20 | Исихара Сангио Кайся Лтд. | Способ борьбы с нежелательным ростом растений |
| US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| JPH04503672A (ja) * | 1989-02-27 | 1992-07-02 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | 放射線増感剤としての新規なナフタレンスルホンアミド |
| TW270116B (es) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
| WO1992020746A1 (en) * | 1991-05-14 | 1992-11-26 | Hybritech, Incorporated | Polymeric compositions having bound antibodies |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| TW224462B (es) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
| CZ256994A3 (en) * | 1992-04-22 | 1995-02-15 | Warner Lambert Co | Peptides, process of their preparation and pharmaceutical compositions based thereof |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| WO1994002474A1 (en) * | 1992-07-17 | 1994-02-03 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| TW287160B (es) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
| CA2121724A1 (en) * | 1993-04-21 | 1994-10-22 | Toshifumi Watanabe | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction |
| US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
| GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
| DE4426346A1 (de) * | 1994-07-25 | 1996-02-01 | Basf Ag | Herbizide Pyrazinderivate |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB2295616A (en) * | 1994-12-01 | 1996-06-05 | Zeneca Ltd | N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists |
| NZ306734A (es) * | 1995-04-04 | 2000-01-28 | Texas Biotechnology Corp |
-
1996
- 1996-03-06 UA UA98010043A patent/UA58494C2/uk unknown
- 1996-06-03 SK SK1680-97A patent/SK282338B6/sk not_active IP Right Cessation
- 1996-06-03 KR KR1019970708807A patent/KR100451523B1/ko not_active Expired - Fee Related
- 1996-06-03 PT PT96919941T patent/PT832082E/pt unknown
- 1996-06-03 CZ CZ19973887A patent/CZ289387B6/cs not_active IP Right Cessation
- 1996-06-03 DE DE69617236T patent/DE69617236T2/de not_active Expired - Lifetime
- 1996-06-03 JP JP50020997A patent/JP3193058B2/ja not_active Expired - Fee Related
- 1996-06-03 ES ES96919941T patent/ES2168487T3/es not_active Expired - Lifetime
- 1996-06-03 RU RU98100054/04A patent/RU2172738C2/ru not_active IP Right Cessation
- 1996-06-03 BR BR9608611A patent/BR9608611A/pt not_active IP Right Cessation
- 1996-06-03 WO PCT/GB1996/001295 patent/WO1996040681A1/en not_active Ceased
- 1996-06-03 EP EP96919941A patent/EP0832082B1/en not_active Expired - Lifetime
- 1996-06-03 AU AU58403/96A patent/AU715041B2/en not_active Ceased
- 1996-06-03 CA CA002219742A patent/CA2219742C/en not_active Expired - Fee Related
- 1996-06-03 HU HU9802300A patent/HUP9802300A3/hu unknown
- 1996-06-03 CN CN96196149A patent/CN1097051C/zh not_active Expired - Fee Related
- 1996-06-03 PL PL96324660A patent/PL187897B1/pl not_active IP Right Cessation
- 1996-06-03 DK DK96919941T patent/DK0832082T3/da active
- 1996-06-03 MX MX9709521A patent/MX9709521A/es unknown
- 1996-06-03 IL IL12246496A patent/IL122464A/en not_active IP Right Cessation
- 1996-06-03 NZ NZ308619A patent/NZ308619A/xx not_active IP Right Cessation
- 1996-06-03 TR TR97/01502T patent/TR199701502T1/xx unknown
- 1996-06-03 AT AT96919941T patent/ATE209200T1/de active
- 1996-06-04 MY MYPI96002166A patent/MY114926A/en unknown
- 1996-06-04 AR ARP960102899A patent/AR003132A1/es active IP Right Grant
- 1996-06-04 TW TW085106632A patent/TW340845B/zh not_active IP Right Cessation
- 1996-06-04 US US08/658,969 patent/US5866568A/en not_active Expired - Lifetime
- 1996-06-06 EG EG50996A patent/EG25227A/xx active
- 1996-06-06 HR HR960272A patent/HRP960272B1/xx not_active IP Right Cessation
-
1997
- 1997-12-05 NO NO19975700A patent/NO314503B1/no not_active IP Right Cessation
-
1998
- 1998-12-14 US US09/211,483 patent/US6060475A/en not_active Expired - Lifetime
-
2000
- 2000-02-15 US US09/504,364 patent/US6258817B1/en not_active Expired - Lifetime
-
2004
- 2004-07-19 GE GE5624A patent/GEP20053470B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9709521A (es) | Compuestos heterociclicos. | |
| BG104544A (en) | Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists | |
| IL133988A0 (en) | Indole derivatives as mcp-1 receptor antagonists | |
| HUP0203870A2 (hu) | Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény | |
| MY117896A (en) | Quinazoline derivatives | |
| AU6461600A (en) | Substituted piperidine compounds useful as modulators of chemokine receptor activity | |
| IL150085A0 (en) | New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | |
| CA2183972A1 (en) | Oxazolidinone derivatives and pharmaceutical compositions containing them | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| TR199701647A2 (xx) | �kame edilmi� purin t�revleri,bunlar�n imalat usul� | |
| BG104630A (en) | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| ZA200110540B (en) | Novel diphenyl-piperidine derivate. | |
| GR3036639T3 (en) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist | |
| EP1019047A4 (en) | ANTITHROMBOTIC AGENTS | |
| MXPA05010783A (es) | Derivados antimicrobianos de [3.1.0] biciclohexilfenil-oxazolidinona y analogos. | |
| IL100458A0 (en) | Pharmaceutical compositions containing antagonists of the quisqualate receptor | |
| HUP0004900A2 (hu) | Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények | |
| DE69927997D1 (de) | Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung | |
| WO2002016327A8 (en) | Benzimidazoles and analogues and their use as neutrophil inhibitors | |
| ZA935045B (en) | Pharmacologically active alfa-(tertiary-aminomethyl)-ben-zenemethanol derivatives | |
| NZ504124A (en) | Phenyl-alkyl-imidazoles and use in treating inflammatory disease | |
| MXPA05011671A (es) | Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos. | |
| UA70953C2 (uk) | Похідні тіобензімідазолу та фармацевтична композиція, що їх містить | |
| MX9706826A (es) | Esteres y amidas de 1,4-piperidina di-sustituida. |